Corporate Overview

About Us

Respironics is the leading provider of innovative solutions for the global sleep and respiratory markets. The Company’s success spans more than three decades and can be traced to a history deeply rooted in ingenuity and a passion to deliver solutions to those in need. This tradition of innovation, combined with an ability to anticipate market needs, is fundamental to the Company. It has made Respironics a name acknowledged worldwide as a pace-setter in the sleep and respiratory markets.

Respironics’ success can be attributed, in part, to its ability to anticipate the needs of the markets it serves, and to provide a range of solutions to address market challenges. Known for expertise in its core areas of sleep and respiratory, the Company is aggressive in its cultivation of promising opportunities such as delivering drugs via the respiratory pathway, seeking methods to assist “problem sleepers” and evolving educational programs to help caregivers in the Neonatal Intensive Care to nurture premature and ill newborns.

Respironics is organized into three primary groups: the Sleep and Home Respiratory Group, the Hospital Group, and the International Group. This decentralized business structure helps to ensure that the Company’s resources are channeled to efficiently meet specific market needs. Each group also has a comprehensive understanding of their markets—from present day healthcare business challenges to future opportunities for emerging technologies and exploration beyond traditional sleep and respiratory markets.

Within each group, there are three separate business units each with a specific mission to either broaden and expand existing business strongholds, or advance new and emerging markets. Empowered to innovate and problem-solve, each business unit contributes to the strength of the Company through the broad spectrum of solutions that it offers the global markets it serves.

Sleep and Home Respiratory Group

Home Respiratory Care
Respironics’ Home Respiratory Care is expanding the Company’s solutions for patients who suffer from chronic respiratory diseases. With a broad range of oxygen, ventilation and monitoring products, Home Respiratory Care offers an array of solutions to help clinicians manage respiratory diseases in a transitional care or home environment.

Home Respiratory Care is dedicated to improving today’s respiratory technologies, while leading research and development of emerging therapies to assist home care providers and health care professionals, as well as patients’ needs. With its rich R&D pipeline and focused efforts, Respironics is positioned for global success in the respiratory marketplace.

View the Home Respiratory Care product line

Sleep Disordered Breathing
The Sleep market is the cornerstone of Respironics’ business strategy. Recognized as the global market leader and innovator in the sleep-disordered breathing marketplace, Respironics leverages its core expertise in treating Obstructive Sleep Apnea (OSA) to develop innovative solutions for the diagnosis, treatment and monitoring of other sleep disorders.

Always on the forefront of innovation, Respironics is known worldwide for driving the sleep therapy market. The Company’s sleep therapy products are designed to encourage patients’ acceptance of OSA therapy through increased comfort. The end result is improved sleep and, ultimately, improved quality of life.

View the Sleep Disordered Breathing product line

Sleep Well Ventures
Sleep Well Ventures moves Respironics beyond our core obstructive sleep apnea (OSA) business into the broader sleep market, which encompasses the millions of people who suffer from undiagnosed and untreated sleep and sleep-related movement disorders such as insomnia, circadian rhythm disorders, or restless legs syndrome. Sleep Well Ventures also works to identify and provide solutions for millions of “problem sleepers” who may not have a specific sleep disorder like the chronic snorer or people who have difficulty falling asleep only occasionally. Through products like Actiwatch®, a device designed to monitor sleep-wake patterns over time and help assess multiple sleep disorders, Sleep Well Ventures seeks to offer sleep professionals, clinicians and their patients solutions that help to improve quality of life through quality sleep.

View the Sleep Well Ventures product line

Hospital Group

Children’s Medical Ventures (ChMV)
Children’s Medical Ventures focuses on improving developmental care outcomes for some of the World’s smallest and most fragile patients. Children’s Medical Ventures is the leading provider of developmentally supportive products for premature babies, and ill infants in the hospital or home offering apnea monitors and recorders, state-of-the-art diagnostic and treatment tools for jaundice, and a line of specialty products that enhance infant growth and development. The business promotes education and hands-on programs for neonatal nurses, and works with parents and caregivers to understand the unique requirements of premature and ill infants. Products and programs are developed to meet the needs of this dynamic market.

Children’s Medical Ventures has proven to be an essential growth driver for Respironics. The business helps extend the Company’s reach in hospital Neonatal Intensive Care Units (NICUs) and in the home.

View the Children's Medical Ventures product line

Critical Care
Respironics’ Critical Care offers a unique platform for managing respiratory patients in a variety of medical environments. Through its Total Ventilation SolutionsSM program, Critical Care gives healthcare providers a diverse and innovative portfolio of invasive and noninvasive ventilators, patient masks, accessories and patient monitoring technologies to help treat, monitor and manage respiratory-impaired patients throughout their diseases.

Total Ventilation Solutions’ comprehensive offerings are designed to provide patients with the best care available while focusing on economical and efficient treatment solutions for health care providers. From pre-hospital admission to long-term acute treatment, Respironics leverages its core expertise and leadership in noninvasive ventilation to assist caregivers in avoiding intubation whenever possible, helping to reduce the patient’s risk of infection and to shorten hospitalization.

View the Critical Care product line

Respiratory Drug Delivery (RDD)
Reflecting its commitment to emerging market needs and providing valued solutions for patients, clinicians and health care providers, Respironics is expanding its presence in the respiratory market space through its Respiratory Drug Delivery business. The Company is exploring enhanced methods of delivering drugs via the respiratory pathway to help treat chronic obstructive pulmonary disease, asthma, pulmonary arterial hypertension, cystic fibrosis and conditions beyond respiratory ailments that would benefit from direct, aerosol delivery methods. Respironics’ unique proprietary technology—Adaptive Aerosol Delivery®—is being integrated into products released in both the European and US markets and offers enormous potential for effective and reliable patient treatment.

View the Respiratory Drug Delivery product line

International Group

With an appreciation for the diversity of the global markets it serves, Respironics is committed to a deep understanding of each country’s distinctive business environment. The strategy has proven to be very successful, enabling Respironics to make solid advances in all key international markets.

International growth is a key component of Respironics’ strategic plan. Targeted international acquisitions, investments in the Company’s international sales and marketing infrastructure, and strong distribution channels have increased Respironics’ presence in the global sleep and respiratory marketplace and positioned the Company for continued expansion. Respironics presently has a direct presence in Germany, France, the United Kingdom, Italy, Switzerland, Japan and China with expansion initiatives in place to increase this direct presence even further.